&nbsp;

FITKitInstructions-Dari.pdf

Dec 1969

Document

FITKitInstructions-Pashto.pdf

Dec 1969

Guidelines and Advice

Fear of Cancer Recurrence Guideline

Status: Current
ID: GL 19-7

Mar 2024

Fumika Test Page (FR)

This is FR page

Regimen

NIVL+RELA

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab and Relatlimab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

Drugs Used:

nivolumab / relatlimab

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

FLAG+IDA+VENE

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Curative

Drugs Used:

IDArubicin,

fludarabine,

cytarabine,

venetoclax (Unfunded)

Quick Link(s):

Regimen Monograph

Jul 2024

Document

no-harm.png

Sep 2024

Regimen

FRUQ

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

fruquintinib (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2024

Guidelines and Advice

First-line treatment of advanced-stage Hodgkin lymphoma

Status: Current
ID: ES 6-25

Oct 2024

Drug

nivolumab / relatlimab

Other Name(s): Opdualag™

Quick Link(s):

Drug Monograph, Patient Info Sheet

Nov 2024

Document

For-More-Information.png

Jan 2025

Regimen

NIVL+IPIL

Cancer Type:

Skin,

Melanoma

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma

New Drug Funding Program

Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma

Drugs Used:

nivolumab,

ipilimumab